<DOC>
	<DOCNO>NCT00984425</DOCNO>
	<brief_summary>Over last decade , improvement investigator ' understand molecular basis cancer lead clinical development protein kinase inhibitor , target pivotal molecule involve intracellular signal pathway implicate tumorigenesis tumor progression . Lapatinib oral selective reversible inhibitor tyrosine kinase domain epidermal growth factor receptor ( EGFR ) human epidermal growth factor receptor type 2 ( HER-2 ) , frequently alter human malignant tumor . Sorafenib oral multi-kinase inhibitor dual-action prevents tumor cell proliferation angiogenesis . The investigator suggest complete blockade ErbB signal network may possible `` sensitize '' tumor cell antiangiogenic therapy , lower tumor cell survival threshold , inhibition vascular endothelial growth factor ( VEGF ) pathway circumvent problem acquire resistance EGFR inhibitor . Based theoretical rationale decide test combination Lapatinib Sorafenib . This phase I trial undertaken ass maximum dose tolerate ( MTD ) , safety/tolerability , pharmacokinetics antitumor efficacy combination patient advance , recurrent metastatic solid cancer refractory available standard treatment .</brief_summary>
	<brief_title>The Treatment Lapatinib Combination With Sorafenib Patients With Advanced Refractory Solid Tumors</brief_title>
	<detailed_description>This dual-agent , prospective , open-label , multi-centric , phase I trial combination Lapatinib Sorafenib patient locally advance , recurrent metastatic solid tumor . This trial conduct determine maximum tolerate dose ( MTD ) , safety/tolerability , pharmacokinetics , antitumor activity two agent give together continuous schedule , patient advance solid tumor . Our ambition recommend safe dose regimen combination subsequent large phase II study , coincide maximum tolerate dose ( MTD ) . The maximum tolerated dose ( MTD ) , define high dosage cohort one six patient experience DLT first treatment cycle . Eligible patient enrol treated accord schema , use 3+3 design ( Fibonacci method modify ) ;</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients locally advance , recurrent metastatic histologically confirm malignancy refractory available standard treatment Prior treatment Lapatinib , Sorafenib agent target EGFR ( trastuzumab ) , Raf , VEGF , VEGFR</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>